Ecoporc Shiga

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

genetically modified recombinant Shiga-toxin-2e antigen

Available from:

CEVA Santé Animale

ATC code:

QI09AB02

INN (International Name):

genetically modified Shiga-toxin-2e antigen

Therapeutic group:

Pigs

Therapeutic area:

Immunologicals for suidae, Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Therapeutic indications:

Active immunisation of piglets from the age of four days, to reduce the mortality and clinical signs of oedema disease caused by Shiga toxin 2e produced by Escherichia coli (STEC). Onset of immunity: 21 days after vaccination. Duration of immunity: 105 days after vaccination.,

Product summary:

Revision: 4

Authorization status:

Authorised

Authorization date:

2013-04-10

Patient Information leaflet

                                15
B. PACKAGE LEAFLET
16
PACKAGE LEAFLET:
ECOPORC SHIGA SUSPENSION FOR INJECTION FOR PIGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
France
Manufacturer responsible for batch release:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Germany
Ceva-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5.
1107 Budapest
Hungary
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ecoporc SHIGA suspension for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
Genetically modified recombinant Stx2e antigen:
≥ 3.2 x 10
6
ELISA units
_ _
ADJUVANT:
Aluminium (as hydroxide)
max. 3.5 mg
EXCIPIENT:
Thiomersal
max. 0.115 mg
Appearance after shaking: yellowish to brownish, homogenous
suspension.
4.
INDICATION(S)
Active immunisation of piglets from the age of 4 days, to reduce the
mortality and clinical signs of
oedema disease caused by Stx2e toxin produced by
_E. coli_
(STEC).
Onset of immunity:
21 days after vaccination
Duration of immunity:
105 days after vaccination
17
5.
CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance, to the
adjuvant or to any of the
excipients.
6.
ADVERSE REACTIONS
Commonly very small local reactions such as mild swelling at the
injection site (maximum of 5 mm)
may be observed, but these reactions are transient and subside within
a short time (up to seven days)
without treatment.
Commonly a slight rise in body temperature (maximum of 1.7 °C) may
occur after injection. But these
reactions subside within a short time (maximum of two days) without
treatment.
Clinical signs such as temporary mild behavioural disturbances can
uncommonly be observed after
application of Ecoporc SHIGA.
The frequency of adverse reactions is defined using the following
convention:
-
very common (more than 1 in 10 animals treate
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ecoporc SHIGA suspension for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCE:
Genetically modified recombinant Stx2e antigen:
≥ 3.2 x 10
6
ELISA units
ADJUVANT:
Aluminium (as hydroxide)
max. 3.5 mg
EXCIPIENT:
Thiomersal
max. 0.115 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Appearance after shaking: yellowish to brownish, homogenous
suspension.
_ _
_ _
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of piglets from the age of 4 days, to reduce the
mortality and clinical signs of
oedema disease caused by Stx2e toxin produced by
_E. coli_
(STEC).
Onset of immunity:
21 days after vaccination
Duration of immunity:
105 days after vaccination
4.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance, to
the adjuvant or to any of the
excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
In case of accidental self-injection or ingestion, seek medical advice
immediately and show the
package leaflet or the label to the physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Commonly very small local reactions such as mild swelling at the
injection site (maximum of 5 mm)
may be observed, but these reactions are transient and subside within
a short time (up to seven days)
without treatment.
Commonly a slight rise in body temperature (maximum of 1.7 °C) may
occur after injection. However,
these reactions subside within a short time (maximum of two days)
without treatment.
Clinical signs such as temporary mild behavioural disturbances can
uncommonly be observed after
application of Ecopor
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-09-2020
Public Assessment Report Public Assessment Report Bulgarian 16-05-2013
Patient Information leaflet Patient Information leaflet Spanish 18-09-2020
Public Assessment Report Public Assessment Report Spanish 16-05-2013
Patient Information leaflet Patient Information leaflet Czech 18-09-2020
Public Assessment Report Public Assessment Report Czech 16-05-2013
Patient Information leaflet Patient Information leaflet Danish 18-09-2020
Public Assessment Report Public Assessment Report Danish 16-05-2013
Patient Information leaflet Patient Information leaflet German 18-09-2020
Public Assessment Report Public Assessment Report German 16-05-2013
Patient Information leaflet Patient Information leaflet Estonian 18-09-2020
Public Assessment Report Public Assessment Report Estonian 16-05-2013
Patient Information leaflet Patient Information leaflet Greek 18-09-2020
Public Assessment Report Public Assessment Report Greek 16-05-2013
Patient Information leaflet Patient Information leaflet French 18-09-2020
Public Assessment Report Public Assessment Report French 16-05-2013
Patient Information leaflet Patient Information leaflet Italian 18-09-2020
Public Assessment Report Public Assessment Report Italian 16-05-2013
Patient Information leaflet Patient Information leaflet Latvian 18-09-2020
Public Assessment Report Public Assessment Report Latvian 16-05-2013
Patient Information leaflet Patient Information leaflet Lithuanian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-09-2020
Public Assessment Report Public Assessment Report Lithuanian 16-05-2013
Patient Information leaflet Patient Information leaflet Hungarian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 18-09-2020
Public Assessment Report Public Assessment Report Hungarian 16-05-2013
Patient Information leaflet Patient Information leaflet Maltese 18-09-2020
Public Assessment Report Public Assessment Report Maltese 16-05-2013
Patient Information leaflet Patient Information leaflet Dutch 18-09-2020
Public Assessment Report Public Assessment Report Dutch 16-05-2013
Patient Information leaflet Patient Information leaflet Polish 18-09-2020
Public Assessment Report Public Assessment Report Polish 16-05-2013
Patient Information leaflet Patient Information leaflet Portuguese 18-09-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 18-09-2020
Public Assessment Report Public Assessment Report Portuguese 16-05-2013
Patient Information leaflet Patient Information leaflet Romanian 18-09-2020
Public Assessment Report Public Assessment Report Romanian 16-05-2013
Patient Information leaflet Patient Information leaflet Slovak 18-09-2020
Public Assessment Report Public Assessment Report Slovak 16-05-2013
Patient Information leaflet Patient Information leaflet Slovenian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 18-09-2020
Public Assessment Report Public Assessment Report Slovenian 16-05-2013
Patient Information leaflet Patient Information leaflet Finnish 18-09-2020
Public Assessment Report Public Assessment Report Finnish 16-05-2013
Patient Information leaflet Patient Information leaflet Swedish 18-09-2020
Public Assessment Report Public Assessment Report Swedish 16-05-2013
Patient Information leaflet Patient Information leaflet Norwegian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 18-09-2020
Patient Information leaflet Patient Information leaflet Icelandic 18-09-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 18-09-2020
Patient Information leaflet Patient Information leaflet Croatian 18-09-2020

View documents history